PTGS2 and ductal breast carcinoma in situ: This is consistent with the observation that COX-2 is not expressed in normal breast tissue but is overexpressed in 43% of her-2/neu-positive invasive breast carcinomas and in 63% of ductal carcinomas in situ [4].